Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients
NCT ID: NCT04184453
Last Updated: 2021-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
5 participants
INTERVENTIONAL
2019-12-23
2022-11-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Deferiprone treated
Deferiprone (25 mg/kg/day) was given to the enrolled patient.
Deferiprone treated
Deferiprone (25 mg/kg/day) was given to the enrolled patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Deferiprone treated
Deferiprone (25 mg/kg/day) was given to the enrolled patients.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with aceruloplasminaemia
* Genetically confirmed diagnosis of aceruloplasminaemia
Exclusion Criteria
* Pregnancy was excluded in women of childbearing age
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Fujian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wan-Jin Chen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wanjin Chen
Role: PRINCIPAL_INVESTIGATOR
Department of Neurology , First Affiliated Hospital Fujian Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurology , First Affiliated Hospital Fujian Medical University
Fuzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
HeJin
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRCTA,ECFAH of FMU [2019]252
Identifier Type: -
Identifier Source: org_study_id